Objectives To examine whether post-chemoradiotherapy (CRT) DCE-MRI can identify rectal cancer patients with pathologic complete response (pCR). Methods From a rectal cancer surgery database [2007][2008][2009][2010][2011][2012][2013][2014] 61 consecutive patients that met the following inclusion criteria were selected for analysis: (1) stage II/III primary rectal adenocarcinoma; (2) received CRT; (3) underwent surgery (4); underwent rectal DCE-MRI on a 1.5-T MRI scanner. Two experienced radiologists, in consensus, drew regions of interest (ROI) on the sagittal DCE-MRI image in the tumour bed. These were exported from ImageJ to in-house Matlab code for modelling using the Tofts model. K trans , K ep and v e values were compared to pathological response. Results Of the 61 initial patients, 37 had data considered adequate for fitting to obtain perfusion parameters. Among the 13 men and 24 women, median age 53 years, there were 8 pCR (22 %). K trans could not distinguish patients with pCR. For patients with 90 % or greater response, mean K trans and K ep values were statistically significant (p = 0.032 and 0.027, respectively). Using a cutoff value of K trans = 0.25 min
Introduction
Diffusion-weighted magnetic resonance imaging (DCE-MRI) in the investigation of rectal cancer tumour response to neoadjuvant treatment has been reported to have variable usefulness . Ongoing investigations using 18 F-FDG-PET, DWI-MRI and magnetization transfer MRI have also been found to be useful [22] [23] [24] [25] . We previously reported our results using post-treatment DCE-MRI in a group of patients that underwent a prospective, investigational chemotherapy-only regimen [1] and we wished to expand our investigation to a group of patients undergoing more standard treatment with combined radiotherapy and chemotherapy.
Several groups have investigated the performance of DCE-MRI among rectal cancer patients after neoadjuvant treatment grouping patients into broad-responder/non-responder categories. Others have focused on the pretreatment prognostic value of DCE-MRI parameters to try to tailor treatment [1, 6, 7, 9, 10, 16, 18] , and yet others have looked for a predictive biomarker such as the change in values due to a particular treatment [7, 8, 16] . Few investigators have focused on the ability of DCE-MRI to identify pathologic complete response (pCR) after all treatment has been completed [1, 13, 18, 20] . This important and growing subset of fortunate patients might potentially safely avoid surgery and undergo non-operative management as validated by several recent studies, albeit not yet the standard approach [24, 26, 27] . One of the main challenges is the successful identification of clinical complete response that would then be considered the prognostic equivalent of pCR. Combined imaging and endoscopy evaluations, currently, are considered likely to be necessary [24] .
Since chemoradiotherapy for the moment remains the mainstay of treatment for locally advanced rectal cancer, our prior study of DCE-MRI in patients only receiving chemotherapy does not suffice to conclude that DCE-MRI would be useful when radiation is used, particularly since radiation has significant local effects on tissues and vessels [1] . Furthermore, there is a paucity of studies looking at posttreatment DCE-MRI, and the three of which we are aware have conflicting results [13, 18, 19] . For this reason, the purpose of our study was to determine, retrospectively, if perfusion parameters derived from post-chemoradiotherapy DCE-MRI could accurately identify patients who, after surgical resection, had achieved pCR, in order to assist in the difficult and important task of identifying patients that could benefit from organ-sparing treatment and avoid unnecessary surgery.
Patients and methods

Patients
This was a retrospective study approved by our institutional review board with a waiver for the need for patient consent. Health Insurance Portability and Accountability Act (HIPAA) compliance was maintained. From a database of patients who underwent surgery for rectal cancer at our centre between 2007 and 2014, 61 consecutive patients who met the following inclusion criteria were selected for review: (1) American Joint Commission on Cancer (AJCC) 7th edition stage II/III primary rectal adenocarcinoma; (2) received chemoradiotherapy (5040 cGy + 5FU/LV) which could also include Binduction^5-fluorouracil/leucovorin and Oxaliplatin (FOLFOX) (n = 8) and which terminated within 8 weeks of performance of the index MRI; (3) underwent curative intent total mesorectal excision (TME) surgery within 14 weeks of CRT; (4) had a diagnostic rectal MRI on a 1.5-T scanner (Excite, G.E. Medical Systems, Waukesha, WI) at our hospital. The final patient cohort, after exclusions, consisted of 37 patients (Fig. 1) . Pathological response of 100 % was defined as Bcomplete response^(pCR) and compared with those who achieved less than 100 % response. We also explored 95 % and 90 % response categories.
Neoadjuvant therapy
All patients underwent CT simulation in the prone position. Patients underwent either 3-dimensional conformal (3DCRT) or intensity-modulated radiotherapy (IMRT) treatment planning with the in-house planning software. 3DCRT plans consisted of three or four orthogonal beams for the pelvic fields, and two lateral beams and one posterior-anterior beam for the boost fields. The planning target volume (PTV) was treated to 45 Gy in 1.8-Gy fractions followed by a 5.4-Gy boost to the PTV boost to a total dose of 5040 cGy. IMRT plans consisted of five to seven equally spaced coplanar fields. The patients treated with IMRT received 45 Gy in 1.8-Gy fractions to PTVand 50 Gy in 2-Gy fractions to the PTV boost as an integrated boost.
Reader assessment
Two experienced radiologists, in consensus, drew regions of interest (ROI) on the sagittal DCE image containing the most obvious tumour/treated tumour bed by comparing the images to other series on the same exam and, where available, pretreatment MRI or CT for tumour location at baseline. The ROI on the most representative section encompassed the entire region with perceptible early enhancement if present or an area in the location of the original tumour bed with a length approximating the most recent imaging extent of the tumour excluding the lumen (Figs. 2, 3 ).
Data acquisition
DCE-MRI images were acquired using a slice-selective 2D or 3D-spoiled gradient echo pulse sequence with slices prescribed in the sagittal plane. Data sets from consecutive patients were examined retrospectively. Acquisition parameter ranges were as follows: TR 3.2-7.8, TE 0.9-4.2, slice thickness 4-10 mm, in-plane voxel resolution 0.83-1.3 mm, temporal resolution 5.99-11.78 s. Acquisition parameter variation was due to the evolution of parameters over the time course of this retrospective study. Patients were scanned on a 1.5-T GE scanner (EXCITE platform. General Electric Medical Systems, Waukesha, WI).
Data processing and analysis
Tumour ROIs were drawn in ImageJ [28] by two radiologists in consensus with expertise in interpreting MR images of the rectum. The ROI from the single most representative tumour slice was transferred to in-house Matlab software and kinetic modelling was performed on all voxels in the ROI.
Prior to kinetic modelling, images were spatially smoothed in-plane with a Gaussian filter (voxel width = 3, sigma = 1). Voxel-wise time course data were fitted to a two-compartment Tofts model [29] and K trans , v e and K ep values were derived. To convert signal intensity to contrast concentration, average precontrast tissue T 1 values were obtained from pretreated patients not included in the study who had undergone multiple flip angle gradient echo imaging for calculation of T 1 on the same 1.5-T MR scanners. An average arterial input function (AIF) was derived from the internal iliac arterial signal time course data in six of the study patients where the artery was included in the excitation volume. Coefficients corresponding to the Parker functional AIF form were derived for this average function [30] and used to generate the AIF at the appropriate time points for each patient in the current study. For each derived parameter, mean, median, mode, and 10th, 75th and 90th percentile values were calculated.
Surgery and histopathology
Our colorectal surgeons, each with specialty training and certified in the performance of TME, removed a patient's rectal c a n c e r u s i n g l o w a n t e r i o r r e s e c t i o n ( L A R ) o r abdominoperineal resection (APR). The specimen was examined with histopathology according to institutional standards. All cases were assessed for surgical margins and other histological features including the percent tumour response, tumour type and differentiation, involvement of the perineural or lymphovascular space by tumour, T stage, and N stage AJCC 7th edition. The percent tumour response was estimated on the basis of the amount of fibrosis and inflammatory tissue versus the amount of residual viable carcinoma in the lesion [31, 32] . 
Statistical methods
The Wilcoxon rank-sum test was used to compare DCE parameters (summary statistics of K trans , v e and K ep ) between patients with histopathologic tumour response of 90 %, 95 % or 100 % and patients without. A p value less than 0.05 is considered statistically significant. We then performed receiver operating characteristic (ROC) analysis to differentiate patients with 90 % response from patients with less response using each parameter. The non-parametric ROC curves and the area under the curves (AUC) were estimated. When the lower limit of 95 % confidence interval (CI) of AUC is greater than 0.5, using the parameter to identify pCR is significantly better than chance. A cutoff point maximizing Youden's index on the ROC curve [24] was also identified along with the observed sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). All analyses were performed in software packages SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and R version 3.1 (The R Foundation for Statistical Computing).
Results
Patients, scanning and treatment
Sixty-one patients with locally advanced rectal cancer satisfied our initial inclusion criteria. Of these, 37 had data considered adequate for fitting to obtain tumour perfusion parameters. The remaining 24 patients were excluded due to poor SNR (N = 11), severe bowel motion (N = 9), inadequate injection delay after scan start (N = 1), voxel size exceeding 10 mm 3 (N = 1) or temporal resolution greater than 12 s (N = 2). Among the 37 patients, seven had stage II rectal cancer and 30 had stage III. There were 13 male and 24 female patients and the median age was 53 years (range 30-85). All patients underwent standard chemoradiotherapy consisting of 50.4 Gy pelvic radiation and 5.5 weeks of 5FU/leucovorin concurrent chemotherapy. Eight patients also underwent induction 5FU/leucovorin combined with oxaliplatin (FOLFOX) induction chemotherapy (8 cycles, 16 weeks). MRI post-treatment was performed a median of 5.0 weeks after the end of CRT (range 2.0-7.7 weeks). A median of 17 days after MRI (range 3-35 days), and a median of 7.7 weeks after the end of CRT (range 5.3-10.3 weeks) patients underwent TME with curative intent. Tumour response ranged from 25 to 100 % (median 80 %). There were eight patients with response of 100 %, 29 patients with response less than 100 %, 26 patients with response less than 95 % and 23 patients with response less than 90 %.
DCE-MRI
There were no significant differences in values of K trans , K ep or v e for patients with greater or less than 100 % and greater or less than 95 % tumour response (Table 1 , p = 0.03). Additionally, the standard deviation of K trans values in the tumour bed was narrower in patients with pCR than those without, suggesting more homogeneous post-treatment non-tumour tissue (p = 0.03). A threshold of 0.25 min −1 emerged as the best mean K trans value to make this distinction with the best combination of sensitivity and specificity and an AUC of 0.71. Although our understanding of cellular level dynamics is still evolving, we interpret our findings, as in our prior work [1] , to reflect that the successful obliteration of abnormally leaky neovasculature in tumour by chemoradiotherapy leads to residual tissue in the tumour bed with more normal flow and permeability. Furthermore, the truly sterilized tumour bed environment may have more homogeneous perfusion characteristics than that of other patients as indicated by a narrower K trans SD. Several investigators have studied DCE-MRI in the treatment of rectal cancer reporting on its use pretreatment [14] [15] [16] 18] , during the course of treatment (deltaK trans ) [4, 8, 13, 15, 19] and after treatment [13, 18, 19] . Intven et al. found that post-CRT K trans was less accurate than the changes in K trans during treatment (deltaK trans ) in distinguishing pCR, and that good responders were more accurately predicted than complete responders (pCR) [19] . This analysis is similar to ours, since we had better accuracy with the 90 % or better response category than with the pCR category. The decrease in K trans values, as was noted in prior studies [13] , was more predictive of 90 % or greater response, but still with a PPVof only 67 %. We did not analyse baseline K trans or deltaK trans since, as a tertiary care centre with many referrals, we do not always have the opportunity to perform the baseline DCE-MRI or have access to outside baseline DCE-MRI kinetic analysis results. Thus, we wanted to test if a single post-treatment DCE-MRI performed at our institution had stand-alone value. The AUC of 0.89 in the Intven study supersedes our AUC of 0.71 for mean K trans . However, the comparability of the studies is somewhat limited, as is often the case, as a result of differing techniques and response definitions. They defined Bgood response^as pCR or near pCR, which includes Mandard TRG 1 (no viable tumour cells) and Mandard TRG 2 (only solitary vital tumour cells in the resection specimen) [33] . This is probably similar to our 90 % or greater tumour response criterion as shown in a comparison of response systems from our institution, where TRG 2 corresponds to 86-99 % tumour response in terms of patient outcomes [32] . Nonetheless, given the retrospective nature of our study and the lower temporal resolution, we still identified predictive value of K trans . This is encouraging for further study of DCE-MRI, perhaps with a more optimized technique where the trade-offs between temporal resolution and adequate signal are optimally balanced.
Similar to our study and the Intven study, the studies of Tong et al. [18] and of Kim et al. [13] did not find posttreatment K trans of value to distinguish pCR from non-pCR patients. The Tong group findings were in keeping with other researchers [15, 16] that found pretreatment K trans predictive of eventual pCR. The Kim group, found only deltaK trans useful to identify overall good responders, as others have found [15, 16] , but this was not true for the pCR group. The clinical implications of our results must be viewed with an eye to DWI-MRI, the other major functional MRI method, which has shown superior results in both qualitative detection of pCR [24] and quantitative evaluation [20] . In fact, using a novel combined functional and volumetric approach, Intven et al. found [20] that the apparent diffusion coefficient (ADC) was superior, with or without added volumetry, in detecting good and compete responses and that DCE-MRI did not add value. ADC for treatment response assessment has been found by most other investigators to be useful [34] [35] [36] [37] , although there is not uniform agreement in the literature [38] .
Although the DCE-MRI techniques available may still be further optimized, deriving model-based K trans values remains burdensome compared with the straightforward visual assessment of signal intensity in DWI-MRI. Recognizing the need to improve workflow if DCE-MRI is to be incorporated into daily MRI interpretation, Martens et al. evaluated a simple semi-quantitative assessment of DCE based on the shape of the enhancement curve in the rectal tumour and found some helpful differences in tumour washout dynamics between good and poor responders [21] . Similarly, Petrillo et al. have developed a parameter based on contrast curve shape for predicting recurrent tumour [39] .
Our study has some limitations, including the sample size and retrospective design. We had multiple exclusions based on image acquisition problems, and this could limit the implementation of this study into clinical practice. As with other studies, actual DCE-MRI parameter values like K trans cannot be easily compared across institutions because of the lack of standards for performance (e.g. field strength, pharmacokinetic model, temporal resolution) of DCE-MRI. Our particular cohort included studies with variable temporal resolution and voxel sizes, which should be made more uniform in future studies. Finally, a fraction of our patients received induction chemotherapy prior to CRT. Although this is not yet a widely adapted treatment paradigm, we still felt that at the end of all treatment, an ability to detect pCR to guide decision-making must be robust since many patients with an intended treatment schema can have alterations during their treatment course.
In conclusion, in a cohort of patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy, although pathologic complete responders could not be confidently identified as a separate group, we found that the mean value of the DCE-MRI-based parameter K trans showed some utility in identifying patients with a pathologic response of 90 % or more and in distinguishing them from patients that had less than 90 % tumour response at surgery. At a threshold of K trans = 0.25, this showed an AUC of 0.71. Further studies comparing DCE-MRI to DWI-MRI are indicated to determine any incremental value in tumour detection.
